8P Pharmacokinetic (PK) profile and food effect of RP-3500, a highly potent and specific inhibitor of ataxia telangiectasia and Rad3-related (ATR) protein kinase in patients (pts) with cancer

S. Lheureux, E. Rosen, E. Lee, D. Spigel,M. Højgaard,E. Fontana, N.B. Mettu,L. Carter,S. Patel, R. Papp, S. May, P. Nejad, D. Ulanet, M. Wainszelbaum, P. Manley,M. Koehler,A.J. Fretland, R. Plummer,T.A. Yap

Annals of Oncology（2022）

引用 0|浏览3

暂无评分

摘要

RP-3500 is an oral ATR inhibitor (ATRi) in development for the treatment of patients (pts) with advanced solid tumors carrying alterations in ATRi-sensitizing genes. The dose-escalation portion of the TRESR study (NCT04497116) evaluated RP-3500 5–200 mg once daily (QD) or twice daily at defined intermittent schedules in 120 pts.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要